Targeted disruption of Stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven T(H)2 cell response

Blood

Volumn 95, Issue 4, 2000, Pages 1249-1257

  Wang, Li Hua ^b   Yang, Xiao Yi ^b   Kirken, Robert A ^b   Resau, James H ^b   Farrar, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIS ACTING ELEMENT; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; MESSENGER RNA; OLIGONUCLEOTIDE; STAT6 PROTEIN;

ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH2 CELL;

EID: 0034651874     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.4.1249.004k39_1249_1257     Document Type: Article

References (59)

1. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138.
2. Carter LL, Dutton RW. Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol. 1996;8:336.
3. Dutton, RW. The regulation of the development of CD8 effector T cells. J Immunol. 1996;157:4287.
4. Umetsu DT, DeKruyff R. Th1 andTh2 CD4+ cells in the pathogenesis of allergic diseases. Proc Soc Exp Biol Med. 1997;215:11.
5. D'Elios M, Del Prete G. Th1/Th2 balance in human disease. Transplant Proc. 1998;30:2373.
6. Romagnani S. Regulation of the development of type 2 T-helper cells in allergy. Curr Opin Immunol. 1994;6:838.
7. Lafaille JJ. The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev. 1998;9:139.
8. Agarwal S, Rao A. Long-range transcriptional regulation of cytokine gene expression. Curr Opin Immunol. 1998;10:345.
9. Mikita T, Campbell D, Wu P, Williamson K, Schindler U. Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol Cell Biol. 1996;16:5811.
10. Lederer JA, Perez VL, DesRoches L, Kim SM, Abbas AK, Lichtman AH. Cytokine transcriptional events during helper T cell subset differentiation. J Exp Med. 1996;184:397.
11. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell. 1997; 89:587.
12. Szabo SJ, Glimcher LH, Ho IC. Genes that regulate interleukin-4 expression in T cells. Curr Opin Immunol. 1997;9:776.
13. Takeda K, Kishimoto T, Akira S. STAT6: its role in interleukin 4-mediated biological functions. J Mol Med. 1997;75:317.
14. Kaplan MH. State is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4:313.
15. Nakamura T, Lee RK, Nam SY, Podack ER, Bottomly K, Flavell RA. Roles of IL-4 and IFN-gamrna in stabilizing the T helper cell type 1 and 2 phenotype. J Immunol. 1997;158:2648.
16. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient mice. Science 1991;254:707.
17. Linehan LA, Warren WD, Thompson PA, Grusby MJ, Berton MT. STAT6 is required for IL-4-induced germline Ig gene transcription and switch recombination. J Immunol. 1998;161:302.
18. Akimoto T, Numata F, Tamura M, et al. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med. 1998;187:1537.
19. Shimoda K, Deursent JV, Sangster MY, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 1996;380:630.
20. Liu KD, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine receptors. Curr Opin Immunol. 1998;10:271.
21. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A. 1997;94:3801.
22. Morriss-Kay GM, Sokolova N. Embryonic development and pattern formation. FASEB J. 1996; 10:961.
23. Isner JM. Oligonucleotide therapeutics: novel cardiovascular targets. Nat Med. 1997;3:834.
24. Bielinska A, Shivdasani RA, Zhang L, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonudeotides. Science. 1990;250:997.
25. Morishita R, Gibbons GH, Horiuchi M, et al. A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855.
26. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against NFκB binding site prevents myocardial infarction as gene therapy. Nat Med. 1997;3:894.
27. Sawa Y, Morishita R, Suzuki K, et al. A novel strategy for myocardial protection using in vivo transfection ot cis element "decoy" against NFκB binding site: evidence for a role of NFκB in ischemic-reperfusion injury. Circulation. 1997; 965(suppl II):II-280.
28. Dzau VJ, Horiuchi M. In vivo gene transfer and gene modulation in hypertension research. Hypertension. 1996;28:1132.
29. Yamashita J, Yoshimasa T, Arai H, et al. Identification of cis-elements of the human endothelin-A receptor gene and inhibition of the gene expression by the decoy strategy. J Biol Chem. 1998; 273:15,993.
30. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res. 1998; 82:1023.
31. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell. 1990;63:601.
32. Tomita N, Morishita R, Higaki J, et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynudeotides against rat angiotensinogen. Hypertension. 1995;26:131.
33. Sharma HW, Perez JR, Higgins-Sochaski K, Hsiao R, Narayanan R. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res. 1996; 16:61.
34. Sharma HW, Narayanan R. The NF-kappaB transcription factor in oncogenesis. Anticancer Res. 1996;16:589.
35. Morishita R, Higaki J, Tomita N, et al. Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation. Hypertension. 1996;27:502.
36. Maeshima Y, Kashihara N, Yasuda T, et al. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. J Clin Invest. 1998;101:2589.
37. Tomita N, Horiuchi M, Tomita S, et al. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. Am J Physiol. 1998;275:F278.
38. Kirken RA, Rui H, Malabarba MG, et al. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and Stat5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain. Cytokine. 1995;7:689.
39. Kotanides H, Nancy CR. Requirement of tyrosine phosphorylation for rapid activation of a DNA binding factor by IL-4. Science. 1993;262:1265.
40. Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 1994; 13:2182.
41. Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J. 1990;9: 4477.
42. Sadowski HB, Shuai K, Darnell JE Jr, Gilman MZ. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science. 1993;261:1739.
43. Schmidt J, Hatzelmann A, Fleissner S, Heimann-Weitschat I, Lindstaedt R, Szelenyi I. Effect of phosphodiesterase inhibition on IL-4 and IL-5 production of the murine Th2-type T cell clone D10.G4.1. Immunopharmacology. 1995;30:191.
44. Takeda KT, Tanaka W, Shi M, et al. Essential role of State in IL-4 signaling. Nature. 1996;380: 627.
45. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol. 1995;12:254.
46. Gavett SH, O'Hearn DJ, Karp CL, et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol. 1997:;272:L253.
47. Paul WE, Ohara J. B-cell stimulatory factor-1/ interleukin 4. Annu Rev Immunol. 1987;5:429.
48. Yoshimoto T, Paul WE. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med. 1994;179:1285.
49. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity. 1995;2:271.
50. Georas SN, Cumberland JE, Burke TF, Chen R, Schindler U, Casolaro V. Stat6 inhibits human interleukin-4 promoter activity in T cells. Blood. 1998;92:4529.
51. Buck HM, Koole LH, van Genderen MH, et al. Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity. Science. 1990;248:208.
52. Matsukura M, Shinozuka K, Zon G, et al. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1987;84:7706.
53. Agrawal S, Goodchild J, Civeira MP, Thornton AH, Sarin PS, Zamecnik PC. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1988;85:7079.
54. Park YG, Nesterova M, Agrawal S, Cho-Chung YS. Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. gene-specific inhibition of tumor growth. J Biol Chem. 1999;274:1573.
55. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE Jr, Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA Cell. 1998;93:827.
56. Hou J, Schindler U, Henzel W, Ho T, Brasseur M, McKnight S. An interleukin-4-induced transcription factor: IL-4 Stat. Science. 1994;265:701.
57. Moriggl R, Kristofic C, Kinzel B, Volarevic S, Groner B. Brinkmann V. Activation of STAT proteins and cytokine genes in human Th1 and Th2 cells generated in the absence of IL-12 and IL-4. J Immunol. 1998;60:3385.
58. Morris SC, Coffman RL, Finkelman FD. In vivo IL-4 responses to anti-IgD antibody are MHC class II dependent and beta 2-microglobulin independent and develop normally in the absence of IL-4 priming of T cells. J Immunol. 1998;160:3299.
59. Huang H, Hu-Li J, Chen H, Ben-Sasson SZ, Paul WE. IL-4 and IL-13 production in differentiated T helper type 2 cells is not IL-4 dependent. J Immunol. 1997;159:3731.